Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Markets & Finance

Street Dislikes Rumored Amgen-Immunex Deal

Neurocrine Biosciences (NBIX) says it saw positive Phase II efficacy results with NBI-34060 immediate release in elderly patients with primary insomnia. Deutsche Banc Alex Brown reiterates its strong buy rating.

Banc of America upgrades Circuit City (CC) to buy from market perform.

RBC Dain Rauscher reiterates its strong buy rating on Nastech Pharmaceutical (NSTK). Yesterday Nastech announced positive results from a Phase II trial of its nasally administered apomorphine for erectile dysfunction.

Bank of America says although acq. of Immunex (IMNX) makes some strategic sense for Amgen (AMGN), the acquisition would be dilutive and would shift the company's focus away from the launch of Aranesp. S&P is reviewing is rating.

WF Van Kasper reportedly downgrades Nike Inc (NKE) to market perform from buy.

Goldman says weak relative performance creates compelling buying opportunity on shares of AOL Time Warner (AOL). The firm reiterates its recommended status.

Goodrich (GR) expects 2001 EPS from continuing operations to exceed $2.80, excluding special items, and $2.45 to $2.55 in 2002. The company says significant progress has been made on the spin-off of its engineered industrial products business.

Moody's reportedly places Calpine Corp. (CPN) on review for a downgrade.

ITT Industries (ITT) wees $3.07 to $3.11 in 2001 EPS, before one-time items. It says that are expected to be off about 4% from 2000, it sees operating margins increasing 20-50 bps due to process improvements and cost control.

Oracle Corp. (ORCL) posts $0.10 compared with $0.11 Q2 EPS on an 11% revenue decline. S&P maintains its accumulate rating.

Tektronix Inc. (TEK) posts $0.12 vs. $0.36 2Q EPS from operations on a 34% sales drop. It sees Q3 revenue down 37%. S&P maintains a hold ratings.

Adobe Systems (ADBE) posts $0.20 compared with $0.34 Q4 EPS from operations on a 26% revenue decline. The company aims for $0.20 to $0.22 Q1 EPS on revenue of $265M to $280M. S&P cuts estimate, maintains accumulate ratings.

Bristol-Myers (BMY) sees lower than expected $2.25 to $2.35 2002 EPS. The company raises its quarterly dividend 2%.

JNI Corp. (JNIC) sees 2002 revenue growth of up to 15% through concurrent expansion of its core fibre channel business, favorable progress with SUNW's server transition, execution of complementary InfiniBand initiatives.

California Micro (CAMD) sees wider than expected $0.38 to $0.40 Q3 loss from operations on revenue of $7M to $7.5M.

Danaher Corp. (DHR) sees $2.30 2001 EPS on essentially flat revenues. The company says Q4 revenue declines will likely be 11% to 13%, with EPS of $0.52. It plans to close 16 facilities and eliminate another 1,100 positions.

Echostar Communications (DISH) is reportedly in talks for a U.S. distribution pact with Vivendi Universal. The deal could lead to Vivend investing about $1.5B in Echostar.

Trimble Navigation (TRMB) sees between breakeven and $0.04 Q4 EPS (adjusted) on $105M to $110M in revenue.

Tribune Co. (TRB) says that November consolidated revenue fell 7%, year-to-date declined 7%.

blog comments powered by Disqus